VBIV Stock Price: VBI Vaccines Inc surges as analyst says firm “could have the best coronavirus vaccine”
Premium|Take advantage of 50% OFF on your first month.
Start your subscription and get access to all our original articles.
You have reached your limit of 5 free articles for this month.
Get Premium without limits for only $9.99 for the first month
Access all our articles, insights, and analysts.
UNLOCK OFFER- NASDAQ: VBIV is set to surge to the highest levels in a month.
- Enthusiasm over VBI Vaccines Inc's potent pan-coronavirus immunization candidate is driving shares higher.
- In a highly competitive race for COVID-19 vaccines, quality may mark a difference.
Vaccinating against more than one coronavirus – and doing it better than competitors – is what VBI Vaccines is seeking. The Massachusets-based pharma firm has performed several preclinical trials on mice and claims that they have provoked a substantial creation of antibodies and other mechanisms to defend against coronaviruses.
The use of the plural is no mistake – one of the candidates is a "trivalent" pan-coronavirus vaccine, protecting against the raging SARS-Cov-2, the 2003-era SARS-CoV, and also MERS-CoV, which dates back to 2015.
Another advantage is that VBI's vaccine may require only one shot – allowing faster distribution of immunization to the world population.
Skeptics have noted that optimism in the preclinical stage may not necessarily translate into success with human subjects. Moreover, several large pharma firms are already conducting Phase 3 tests – injecting their solutions to around 30,000 subjects.
Nevertheless, the AstraZeneca/University of Oxford project – considered the most advanced – may work for only 12-24 months. With dozens of companies working on a solution – and limited production capacity – there is still time for smaller firms to provide potentially better solutions.
The high level of antibodies created – at least among mice – may be a differentiating factor. That has led Steven Seedhouse, an analyst with Raymond James, to upgrade the stock to "strong-buy", adding that "VBI may be in an entirely different ballpark for potency vs. any other vaccine we've seen."
VBIV Stock Forecast
NASDAQ: VBIV is quoted at around $4.50 in Friday's pre-market trading, building on top of its whopping 32% leap on Thursday. VBI Vaccines is on course to hit the highest since late July, a one-month high. The 52-week high of $6.83 is the bullish upside target. Support awaits at $3.19, August's low.
- NASDAQ: VBIV is set to surge to the highest levels in a month.
- Enthusiasm over VBI Vaccines Inc's potent pan-coronavirus immunization candidate is driving shares higher.
- In a highly competitive race for COVID-19 vaccines, quality may mark a difference.
Vaccinating against more than one coronavirus – and doing it better than competitors – is what VBI Vaccines is seeking. The Massachusets-based pharma firm has performed several preclinical trials on mice and claims that they have provoked a substantial creation of antibodies and other mechanisms to defend against coronaviruses.
The use of the plural is no mistake – one of the candidates is a "trivalent" pan-coronavirus vaccine, protecting against the raging SARS-Cov-2, the 2003-era SARS-CoV, and also MERS-CoV, which dates back to 2015.
Another advantage is that VBI's vaccine may require only one shot – allowing faster distribution of immunization to the world population.
Skeptics have noted that optimism in the preclinical stage may not necessarily translate into success with human subjects. Moreover, several large pharma firms are already conducting Phase 3 tests – injecting their solutions to around 30,000 subjects.
Nevertheless, the AstraZeneca/University of Oxford project – considered the most advanced – may work for only 12-24 months. With dozens of companies working on a solution – and limited production capacity – there is still time for smaller firms to provide potentially better solutions.
The high level of antibodies created – at least among mice – may be a differentiating factor. That has led Steven Seedhouse, an analyst with Raymond James, to upgrade the stock to "strong-buy", adding that "VBI may be in an entirely different ballpark for potency vs. any other vaccine we've seen."
VBIV Stock Forecast
NASDAQ: VBIV is quoted at around $4.50 in Friday's pre-market trading, building on top of its whopping 32% leap on Thursday. VBI Vaccines is on course to hit the highest since late July, a one-month high. The 52-week high of $6.83 is the bullish upside target. Support awaits at $3.19, August's low.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.